Clinical Trial Update: GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of GM-CT-01 combined with 5-fluorouracil as third- or fourth-line therapy for metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• GM-CT-01 (GM-CT-01)

Snippet

Sponsor: Galectin Therapeutics Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED